Metactive Medical Inc., an Olathe-based bio-medical firm, said it recently received $2 million in additional financing from investors that include the Kansas Bioscience Authority. Metactive had previously raised $5 million in early-stage funding.
The company is developing endovascular medical devices for the treatment of peripheral vascular and neurovascular diseases.
Metactive also announced the appointment of David Ferrera to its board. Ferrera is president and chief technology officer of Blockade Medical, based in Irvine, Calif.